ORIGINAL ARTICLE

Change in serum levels of inflammatory markers reflects response of percutaneous catheter drainage in symptomatic fluid collections in patients with acute pancreatitis

Bipadabhanjan Mallick,* Shalu Tomer,† Sunil K Arora,‡ Anupam Lal,§ Narendra Dhaka,* Jayanta Samanta,* Saroj K Sinha,* Vikas Gupta,† Thakur Deen Yadav§ and Rakesh Kochhar*  

Departments of *Gastroenterology, †Immunopathology, ‡Radiodiagnosis and §General Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Key words  
acute pancreatitis, C-reactive protein, interleukin-10, interleukin-6, inflammatory markers, interleukins, percutaneous catheter drainage.

Accepted for publication 18 January 2019.

Correspondence  
Professor Rakesh Kochhar, Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.  
Email: dr_kochhar@hotmail.com

Declaration of conflict of interest: The authors declare that they have no conflict of interest.

Abstract

Background: Percutaneous catheter drainage (PCD) is used as the first step in the management of symptomatic fluid collections in patients with acute pancreatitis (AP). There are limited data on the effect of PCD on inflammatory markers.

Aim: To study the effects of PCD on serum levels of C-reactive protein (CRP), IL-6, and IL-10 and its correlation with the outcome.

Methods: Consecutive patients of AP with symptomatic fluid collections undergoing PCD were evaluated for serum levels of CRP, IL-6, and IL-10 before PCD and at 3 and 7 days after PCD. Resolution of organ failure (OF), sepsis, and pressure symptoms was considered to demonstrate the success of PCD. Changes in levels following PCD were correlated with outcome.

Results: Indications of PCD in 59 patients (age 38.9 ± 13.17 years, 49 male) were suspected/documentated infected pancreatic necrosis (n = 45), persistent OF (n = 40), and pressure symptoms (n = 7). A total of 49 (83.1%) patients improved with PCD, five patients required surgery, and six died. A significant difference was noted between baseline levels of CRP (P = 0.026) and IL-6 (P = 0.013) among patients who improved compared to those who worsened following PCD. Significant decrease (P < 0.01) on day 7, was noted. The percentage of the decrease of IL-6 levels on day 3 and of CRP on day 7 correlated with the outcome.

Conclusion: PCD is associated with a significant decrease in CRP, IL-6, and IL-10 levels. Percentage decrease in IL-6 on day 3 and CRP on day 7 correlated with the outcome of patients managed with PCD.

Introduction

Acute pancreatitis (AP) is an acute inflammatory disease of the pancreas with involvement of both local tissues and distant organs. During an episode of AP, large quantities of cytokines, such as interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), and interleukin-8 (IL-8), are produced, which have a key role in the pathogenesis of AP. Cytokines stimulate transcription factor NF-κB, which plays a pivotal role in the expression of numerous genes involved in inflammation. This cytokine storm is followed by an anti-inflammatory response, and the severity depends on the balance between inflammatory and anti-inflammatory response. The evolution of AP occurs in two phases: an early phase (usually within the first week of onset) and a subsequent phase occurring after the first week of the onset of the disease. During the first phase, the severity of pancreatitis is related to the systemic inflammatory response elicited by the tissue injury, and in the second phase, the severity of disease and mortality is usually related to the infection of pancreatic necrosis.

The revised Atlanta classification of severity of AP is based on the presence/absence of organ failure (OF) and/or fluid collections. Percutaneous catheter drainage (PCD) of symptomatic fluid collections in patients with AP is a minimally invasive alternative to surgical treatment and has lead to a paradigm shift in the management of pancreatic fluid collections from open necrosectomy to minimally invasive treatment. Most of the centers have now adopted the “step up” approach based on the PANTER trial, the first step being percutaneous or endoscopic catheter drainage. A recent meta-analysis showed that the non-operative approach to percutaneous drainage is successful in up to 50% of patients with infected necrosis. Van Baal et al. also reported that, when PCD is used in necrotizing pancreatitis,
surgical necrosectomy could be avoided in over half of the patients. Patients failing to recover with medical management and PCD need a step up approach to treatment in the form of single- or multiport percutaneous endoscopic necrosectomy, or video-assisted retroperitoneal debridement (VARD). Patients not responding to these minimally invasive necrosectomy techniques will ultimately require surgical necrosectomy, with higher mortality up to 40%. 

While the usefulness of serum levels of IL-6, IL-10, and C-reactive protein (CRP) in the assessment of the severity of AP and mortality have been studied, they have not been evaluated for assessing the outcome of PCD. A few studies have documented that the levels of CRP fall after PCD. One study showed that there was a correlation between the decrease in CRP levels and outcome of patients after PCD. There are no such data on IL-6 and IL-10. Hence, we planned the current study to observe the effect of PCD on serum levels of CRP, IL-6, and IL-10 and whether the change in levels after PCD could correlate with the outcome of the patients.

**Patients and methods**

This study comprised of all patients of AP having fluid collection(s) admitted to the Gastroenterology and Surgery services at the Postgraduate Institute of Medical Education and Research, a tertiary care referral center in Chandigarh, India, who underwent PCD as a part of treatment between July 2015 and December 2016. This prospective observational study was approved by the Institute Ethics Committee, and informed consent was obtained from all the patients before inclusion.

**Patients.** A total of 105 patients with AP aged >12 years having fluid collection(s) were admitted in the hospital, 59 of whom underwent PCD and formed the study group. Patient with underlying chronic pancreatitis or those having undergone any prior endoscopic/radiological/surgical intervention or PCD outside the study center were excluded from the study. Patients with known severe pre-existing comorbid illnesses were also excluded.

**Treatment protocol.** The diagnosis of AP was made by any two of the following three factors: (i) abdominal pain consistent with AP; (ii) serum lipase activity (or amylase activity) at least three times greater than the upper limit of normal; and (iii) characteristic findings of AP on contrast-enhanced computed tomography (CT/USG) until discharge, and thereafter, imaging was performed. Intra-abdominal pressure (IAP) was measured 6–12 h before PCD insertion using the Foley manometer technique. The technique used for PCD was either Tandem trocar or Seldinger technique depending on the size and site of collection(s), and an initial catheter size of 12 Fr was used for PCD. The first aspirated fluid sample was transferred to the bacteriology laboratory in a sterile container for culture. The catheter was left for gravity drainage and flushed with normal saline at least once a day.

**Post-PCD follow-up.** Postprocedure, patients were monitored for improvement in OF, control of infection, and relief of pressure symptoms, and IAP was measured at 24 and 48 h post-PCD. In the event of no improvement within 72 h, the catheters were upsized to a maximum of 16 Fr, or additional drainage was established for any residual collection(s). After the drainage procedure, antibiotic therapy was modified according to the culture sensitivity report and was continued for at least 10–14 days. All patients were followed up clinically and radiologically (USG/CT) until discharge, and thereafter, imaging was repeated at 2–4 weeks until resolution or surgery/death. Patients who failed to recover or worsened with medical management and PCD underwent surgical necrosectomy.

All immediate periprocedural, as well as delayed, complications of PCD were noted. External pancreatic fistula (EPF) with clear pancreatic secretion of >200 mL per day persisting beyond 2 weeks of insertion of PCD were managed using pancreatic duct stenting. Patients with slippage and blockade of catheter were readmitted and managed with reintroduction of PCD. Bleeding from the PCD site was investigated and managed as per the indication.

**Inflammatory markers.** Blood samples were collected for CRP, IL-6, and IL-10 on the day of PCD and 3 days and 7 days after PCD. Quantitative CRP estimation was performed by using latex-enhanced nephelometry. Samples for IL-6 and IL-10 estimation was performed using commercially available ELISA kits (Diaclone ELISA kit, Diaclone SAS, France).

**Statistical analysis.** All data were entered on a personal computer using Microsoft Excel 2010 and SPSS software. The data were analyzed using SPSS software (version 22.0, IBM, USA). Quantitative or numerical variables were represented with measures of central location, such as mean; median; and measures of dispersion, that is, standard deviation, standard error.
The correlation between inflammatory marker levels before PCD and the duration of OF, duration of PCD, and hospital stay was calculated by the Pearson correlation test \((r)\) while the correlation with the requirement of additional PCD, requirement of upgrading of PCD, requirement surgery, and mortality was calculated by the Spearman rank test \((\rho)\). For more than two groups, one-way ANOVA was used. A \(P\) value of less than 0.05 was statistically significant.

**Results**

Of the 59 patients, 23 (39%) required intensive care, with 8 patients requiring ventilator support and 4 patients requiring dialysis. Table 1 demonstrates the patient characteristics. The indications of PCD were suspected/documented infected necrosis in 45 patients, persistent OF in 40 patients, and pressure symptoms in 7 patients. One PCD was inserted in 32 (54.2%) patients, whereas 27 (45.8%) patients had \(\geq 2\) PCDs with mean of 1.64 ± 0.78 PCDs per patient. The first PCD was upgraded in 27 (45.8%) patients. Overall, 49 of 59 (83.1%) patients improved after PCD, with the resolution of fluid collections, OF, sepsis, and/or pressure symptoms (Fig. 1). Five patients required open necrosectomy for failure to respond with PCD, and six (10.2%) patients died, including one patient after surgery (Fig. 2). The mean hospital stay was 30.6 ± 17.11 days.

All our study patients were discharged with PCD in situ. A total of 37 complications occurred in 33 of 55(60%) patients, EPF being the most common \((n = 19)\), followed by slippage of PCD catheter \((n = 10)\) and blockade of PCD catheter \((n = 7)\), and one patient developed a bleed through the PCD catheter. Ten of the patients with EPF were managed conservatively, and the fistula output decreased gradually until it stopped. The other nine patients underwent successful endoscopic pancreatic stenting with resolution of fistula. Patients with slippage or block of PCD were readmitted, and repositioning of PCD was performed. One patient who developed bleeding from the cavity wall was successfully managed with surgical packing. The median duration of PCD1 was 19 (range; 5–94) days, PCD2 was 26 (range; 4–96) days, and PCD3 was 30.5 (range; 5–90) days.

**Levels of inflammatory markers.** The mean values of CRP before the placement of PCD were 153.71 ± 105.10 mg/L, of IL-614.52 ± 54.32 pg/mL, and that of IL-10 were 31.91 ± 15.62 pg/mL. Of the 59 patients, 43 (72.9%) had acute necrotic collection (ANC) and 16 (27.1%) had walled-off necrosis (WON). The mean baseline values of CRP in ANC and WON were 148.86 ± 93.76 mg/L and 166.75 ± 133.59 mg/L, respectively \((P = 0.56)\). The mean baseline values of IL-6 in ANC and WON were 184.51 ± 53.07 pg/mL and 142.76 ± 47.75 pg/mL, respectively \((P = 0.007)\). The mean baseline values of IL-10 in ANC and WON were 35.38 ± 16.29 pg/mL and 22.57 ± 8.55 pg/mL, respectively \((P = 0.004)\).

Table 2 demonstrates the correlation between baseline levels of inflammatory markers and outcome measures. Serum CRP levels correlated positively with the duration of OF and mortality, whereas serum IL-6 levels correlated with mortality.

**Effect of PCD on inflammatory markers.** Figure 3 depicts the levels of inflammatory markers before PCD and 3 days and 7 days after insertion of PCD. There was a significant decrease in all the three markers on day 3 after the PCD was inserted, with further decrease on day 7 as well. Table 3 compares the baseline levels of inflammatory markers among 49 patients who improved and 10 patients who did not. Levels of all the three markers were higher among the patients who worsened or required surgery. Baseline CRP and IL-6 levels were significantly higher in patients who did not improve or worsened after PCD compared to those who improved \((P < 0.05)\).

Table 4 gives the correlation between the decrease of inflammatory markers on days 3 and 7 post-PCD and improvement after PCD. The correlation of the decrease of the three markers with improvement after PCD did not reach statistical significance. When the percentage of the decrease of inflammatory markers on days 3 and 7 after PCD insertion was compared between patients who improved \((n = 49)\) and those who worsened or required surgery or died \((n = 10)\), the decrease of IL-6 levels on day 3 and that of CRP levels on day 7 correlated positively with the outcome of patients \((P < 0.05)\).

**Discussion**

We evaluated serum CRP, IL-6, and IL-10 levels in 59 patients with symptomatic pancreatic fluid collections before PCD and 3 and 7 days after PCD. There was a significant difference between baseline levels of CRP and IL-6 among patients who improved after PCD \((n = 49)\) compared to those who worsened \((n = 10)\) but not in the levels of IL-10. There was a significant decline in the levels of all three markers after 3 and 7 days of PCD, and the percentage decrease of CRP on day 7 post-PCD and that of IL-6 on day 3 post-PCD correlated with the outcome.

Serum CRP levels have been found to correlate with the severity of AP and outcome.\(^{15-18,28}\) Serum CRP values reach a peak on day 3 of pancreatitis and decline after that.\(^{15}\) Patients with severe AP with a high Acute Physiology and Chronic Health Evaluation (APACHE) score can have persistently elevated levels beyond 7 days.\(^5\) It is expected that if there is

---

**Table 1** Patient characteristics \((n = 59)\)

| Age (mean ± SD) | 38.9 ± 13.17 years |
|-----------------|-------------------|
| Gender (M:F)    | 49:10             |
| Etiology of pancreatitis |              |
| Alcohol         | 36 (61%)          |
| Gall stone      | 12 (20.3%)        |
| Others          | 11 (18.7)         |
| Organ failure   |                   |
| Acute lung injury| 42 (71.2%)        |
| Acute kidney injury| 14 (23.7%)      |
| Cardiovascular system failure | 6 (10.2%) |
| Infection of pancreatic collection |       |
| Infected        | 38 (64.4%)        |
| Sterile         | 21 (35.6%)        |
| CT severity index (CTSI) (mean ± SD) | 9.49 ± 1.04 |
| Interval between pain onset to hospitalization (median/range) | 13 days (1–90 days) |
| Interval between pain onset to first PCD (mean ± SD) | 23.76 ± 17.43 days |

PCD, percutaneous catheter drainage.
Inflammatory markers after drainage

Figure 1  Contrast-enhanced computed tomography (CECT) abdomen; (a) before percutaneous catheter drainage (PCD), (b) with PCD, (c) after PCD.

CRP, C-reactive protein; PCD, percutaneous catheter drainage.

Table 2  Correlation of inflammatory markers with outcome

| Outcome parameters                  | Serum CRP |                   | Serum IL-6 |                   | Serum IL-10 |                   |
|-------------------------------------|-----------|------------------|------------|------------------|--------------|------------------|
|                                     | Correlation | Significance (P) | Correlation | Significance (P) | Correlation | Significance (P) |
| Duration of organ failure (r)       | 0.33       | 0.01             | 0.06       | 0.72             | 0.07         | 0.68             |
| Duration of PCD (r)                 | 0.03       | 0.80             | 0.01       | 0.78             | -0.14        | 0.28             |
| Requirement of additional PCD (rho) | 0.19       | 0.14             | 0.05       | 0.67             | 0.14         | 0.27             |
| Requirement of upgradation of PCD (rho) | 0.13       | 0.32             | 0.03       | 0.77             | -0.08        | 0.52             |
| Hospital stay (r)                   | 0.02       | 0.87             | 0.20       | 0.12             | 0.09         | 0.48             |
| Requirement of surgery (rho)        | 0.11       | 0.37             | 0.05       | 0.72             | -0.01        | 0.97             |
| Mortality (rho)                     | 0.26       | 0.04             | 0.33       | 0.01             | 0.17         | 0.18             |

*p One patient died after surgery

Inflammation in patients with infected necrosis, the serum CRP level would tend to remain elevated. Navalho et al. reported that their patients with infected fluid collections had CRP levels in the range of 172.8–190.9 mg/l at the time of PCD. We also found that our patients with fluid collections requiring PCD had elevated CRP levels more than 3 weeks after the onset of pancreatitis, and the levels correlated with the persistence of OF and subsequent mortality. We have, for the first time, noted that baseline serum CRP levels were higher among patients who did not improve after PCD. There are a few studies on changes in CRP...
levels in patients undergoing PCD. Baudin et al.\textsuperscript{19} and Kotan et al.\textsuperscript{20} were the first to show that CRP levels decrease following PCD. Navalho et al.\textsuperscript{23} showed that, after PCD, the serum CRP levels fell significantly and correlated with the success of the procedure. Ai et al.\textsuperscript{21} compared the decrease in CRP levels after PCD and surgical necrosectomy and documented that CRP levels return to normal 24.9 days after PCD and 42.1 days after surgery. We estimated CRP levels on days 3 and 7 after PCD and found that the fall of levels correlated with the outcome of PCD.

Among the cytokines studied in patients with AP, levels of both IL-6 and IL-10 are elevated in AP and correlate with severity, OF, and mortality.\textsuperscript{29–31} Brivet et al.\textsuperscript{32} observed that levels of both IL-6 and IL-10 remain elevated in systemic circulation for up to 15 days in severe pancreatitis. The persistence of inflammation or OF or the occurrence of infection has also been found to be associated with persistently elevated IL-6 and IL-10 levels.\textsuperscript{33}

We observed higher levels of both IL-6 and IL-10 in our patients with pancreatic collections more than 3 weeks after the onset of pain. When we correlated baseline IL-6 and IL-10 levels with outcome measures, there was a positive correlation between mortality and IL-6 levels but not with IL-10 levels. After the institution of PCD, there was a significant decrease in IL-6 and IL-10 levels on day 3, which fell further on day 7 after PCD. There is only one previous study that had looked at IL-6 and IL-10 levels after PCD in which Liu et al.\textsuperscript{22} reported a decrease in IL-6 and IL-10 after PCD. They have compared the effect of

Table 3  Comparison between patients who improved and those who did not with PCD

| Parameters | Patients who improved | Patient who did not improve | Significance ($P$) |
|------------|-----------------------|----------------------------|-------------------|
| CRP (mg/L) | 146.48 ± 111.60       | 189.10 ± 55.5              | 0.026             |
| IL-6 (pg/ml) | 166.09 ± 51.21       | 215.81 ± 52.40             | 0.013             |
| IL-10 (pg/mL) | 30.28 ± 14.13       | 39.90 ± 20.53              | 0.076             |

Table 4  Correlation of fall of inflammatory markers with outcome

| Parameters | Outcome | Before PCD | Day 3 | Day 7 | % of fall on day 3 | % of fall on day 7 | p1 | p2 | p3 | p4 |
|------------|---------|------------|-------|-------|-------------------|-------------------|-----|-----|-----|-----|
| CRP (mg/L) | Improved | 146.48 ± 111.60 | 113.7 ± 37.86 | 113.7 ± 37.86 | 75.58 ± 24.10 | 75.58 ± 24.10 | 0.31 | 0.10 | 0.04 | 0.04 |
|            | Not improved | 189.10 ± 55.5 | 173.6 ± 55.7 | 173.6 ± 55.7 | 81.9 ± 9.25 | 81.9 ± 9.25 | 0.04 | 0.04 | 0.04 | 0.04 |
| IL-6 (pg/mL) | Improved | 166.09 ± 51.21 | 121.3 ± 38.87 | 121.3 ± 38.87 | 85.18 ± 23.56 | 85.18 ± 23.56 | 0.28 | 0.28 | 0.28 | 0.28 |
|            | Not improved | 215.81 ± 52.40 | 184.3 ± 55.7 | 184.3 ± 55.7 | 63.57 ± 10.29 | 63.57 ± 10.29 | 0.04 | 0.04 | 0.04 | 0.04 |
| IL-10 (pg/mL) | Improved | 30.28 ± 14.13 | 25.96 ± 14.13 | 25.96 ± 14.13 | 23.21 ± 6.66 | 23.21 ± 6.66 | 0.27 | 0.27 | 0.27 | 0.27 |
|            | Not improved | 39.90 ± 20.53 | 31.84 ± 21.25 | 31.84 ± 21.25 | 23.24 ± 16.16 | 23.24 ± 16.16 | 0.07 | 0.07 | 0.07 | 0.07 |

CRP, C-reactive protein; PCD, percutaneous catheter drainage.

Figure 3  Levels of inflammatory markers before and days 3 and 7 post-PCD. PCD, percutaneous catheter drainage.

Table 4  Correlation of fall of inflammatory markers with outcome

| Parameters | Outcome | Before PCD | Day 3 | Day 7 | % of fall on day 3 | % of fall on day 7 | p1 | p2 | p3 | p4 |
|------------|---------|------------|-------|-------|-------------------|-------------------|-----|-----|-----|-----|
| CRP (mg/L) | Improved | 146.48 ± 111.60 | 113.7 ± 37.86 | 113.7 ± 37.86 | 75.58 ± 24.10 | 75.58 ± 24.10 | 0.31 | 0.10 | 0.04 | 0.04 |
|            | Not improved | 189.10 ± 55.5 | 173.6 ± 55.7 | 173.6 ± 55.7 | 81.9 ± 9.25 | 81.9 ± 9.25 | 0.04 | 0.04 | 0.04 | 0.04 |
| IL-6 (pg/mL) | Improved | 166.09 ± 51.21 | 121.3 ± 38.87 | 121.3 ± 38.87 | 85.18 ± 23.56 | 85.18 ± 23.56 | 0.28 | 0.28 | 0.28 | 0.28 |
|            | Not improved | 215.81 ± 52.40 | 184.3 ± 55.7 | 184.3 ± 55.7 | 63.57 ± 10.29 | 63.57 ± 10.29 | 0.04 | 0.04 | 0.04 | 0.04 |
| IL-10 (pg/mL) | Improved | 30.28 ± 14.13 | 25.96 ± 14.13 | 25.96 ± 14.13 | 23.21 ± 6.66 | 23.21 ± 6.66 | 0.27 | 0.27 | 0.27 | 0.27 |
|            | Not improved | 39.90 ± 20.53 | 31.84 ± 21.25 | 31.84 ± 21.25 | 23.24 ± 16.16 | 23.24 ± 16.16 | 0.07 | 0.07 | 0.07 | 0.07 |

p1, significance of fall on day 3; p2, significance of fall on day 7; p3, significance of percentage of fall on day 3; p4, significance of percentage of fall on day 7.
PCD alone with PCD plus abdominal fluid drainage on levels of IL-6 and IL-10. In a different setting, Bakker et al.34 studied the impact of endoscopic and surgical necrosectomy on serum IL-6 levels and observed a significant decrease in IL-6 levels. These results suggest that both PCD and endoscopic necrosectomy result in a decrease in the levels of inflammatory cytokines.

Our data are in accordance with that of Liu et al.,22 that PCD results in a decrease of inflammatory markers denoting a reduction of inflammatory cytokine drive. In our patients, this happened in all the patients subjected to PCD, with a greater decrease in the patients who improved after PCD. Removal of pancreatic necrosis and/or infected tissue leads to the interruption of the inflammatory cascade and a decrease in IAP resulting in the decrease of serum inflammatory markers.35 The fact that IL-6 levels fell at day 3 post-PCD and CRP levels at day 7 post-PCD in our study suggests that a halt in macrophage stimulation by IL-6 is followed by a decrease in CRP production. While we estimated levels of CRP, IL-6, and IL-10 only on days 3 and 7 of PCD, other workers have estimated levels of CRP periodically until the removal of the PCD catheter.19,23 It has been periodically noted that the levels of inflammatory markers did not return to normal even at the time of removal of the PCD catheter in these studies.19,22,23 Our result showed that, although the decrease in absolute values of the three markers did not correlate with the outcome, the percentage fall in levels on days 3 and 7 correlated with the outcome. By extending the estimation beyond 7 days, till discharge or till removal of catheter, we might have obtained a better statistical correlation of fall in levels, but a 3-day and 7-day estimation is a more practical and feasible approach.

Our results suggest that monitoring the levels of CRP, IL-6, and IL-10 after PCD can be used to predict the outcome of PCD. Patients who do not show a decrease of CRP and IL-6 are candidates who may require a stepping up of the treatment strategy with endoscopic or surgical necrosectomy. However, our study suffers from some limitations. We did not have levels of the three markers on the day of hospitalization. As such, our hospital being a tertiary care hospital, the mean interval between onset of pain and hospitalization was 13 days. We did not have a control group of patients with fluid collections who did not require PCD. We estimated levels of CRP, IL-6, and IL-10 on days 3 and 7 post-PCD only. We did not estimate the levels until the day of discharge or until removal of PCD. Our premise was to see if a trend in the change of levels of the inflammatory markers could predict the outcome.

In conclusion, percutaneous drainage of peripancreatic fluid collections is rewarding in a majority of patients. Serum levels of CRP and IL-6 before placement of PCD correlated with the outcome of patients managed with PCD. PCD leads to a significant fall in inflammatory markers, which can be used to correlate with the outcome. We propose that the monitoring of levels of CRP and IL-6 should be performed after PCD to identify poor responders who may require stepping up of the treatment strategy.

REFERENCES

1 Frossard JL, Hadengue A, Pastor CM. New serum markers for the detection of severe acute pancreatitis in humans. Am. J. Respir. Crit. Care Med. 2001; 164: 162–70.

2 Wilson PG, Manji M, Neoptolemos JP. Acute pancreatitis as a model of sepsis. J. Antimicrob. Chemother. 1998; 41 Suppl. A: 51–63.

3 Kylanpaa L, Rakoczy Z Jr, O’Reilly DA. The clinical course of acute pancreatitis and the inflammatory mediators that drive it. Int. J. Inflamm. 2012; 2012: 360685.

4 Rakonczay Z Jr, Hegyi P, Takács T, McCarron J, Saluja AK. The role of NF-kappaB activation in the pathogenesis of acute pancreatitis. Gut. 2008; 57: 259–67.

5 Shen Y, Deng X, Xu N, Li Y, Miao B, Cui N. Relationship between the degree of severe acute pancreatitis and patient immunity. Surg. Today. 2015; 45: 1009–17.

6 Banks PA, Bolten TL, Dervenis C et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013; 62: 102–11.

7 Besselink MG, van Santvoort HC, Nieuwenhuijs VB et al. Minimally invasive ‘step-up approach’ versus maximal necrosectomy in patients with acute necrotising pancreatitis (PANTER trial): design and rationale of a randomised controlled multicenter trial [ISRCTN13975868]. BMC Surg. 2006; 6: 6.

8 Mouli VP, Sreenivas V, Garg PK. Efficacy of conservative treatment, without necrosectomy, for infected pancreatic necrosis: a systematic review and meta-analysis. Gastroenterology, 2013; 144: 533–40.

9 van Baal MC, van Santvoort HC, Bolten TL et al. Systematic review of percutaneous catheter drainage as primary treatment for necrotizing pancreatitis. Br. J. Surg. 2011; 98: 18–27.

10 Dhingra R, Srivastava S, Behra S et al. Single or multiport percutaneous endoscopic necrosectomy performed with the patient under conscious sedation is a safe and effective treatment for infected pancreatic necrosis. Gastrointest. Endosc. 2015; 81: 351–9.

11 Runzi M, Niebel W, Goebell H, Gerken G, Layer P. Severe acute pancreatitis: nonsurgical treatment of infected necroses. Pancreas. 2005; 30: 195–9.

12 Malmstrom ML, Hansen MB, Andersen AM et al. Cytokines and organ failure in acute pancreatitis: inflammatory response in acute pancreatitis. Pancreas. 2012; 41: 271–7.

13 Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut. 2000; 47: 546–52.

14 Phillip V, Steiner JM, Algul H. Early phase of acute pancreatitis: assessment and management. World J. Gastrointest. Pathophysiol. 2014; 5: 158–68.

15 Inamura T, Tanaka S, Yoshida H et al. Significance of measurement of high-sensitivity C-reactive protein in acute pancreatitis. J. Gastroenterol. 2002; 37: 935–8.

16 Cardoso FS, Ricardo LB, Oliveira AM et al. C-reactive protein prognostic accuracy in acute pancreatitis: timing of measurement and cutoff points. Eur. J. Gastroenterol. Hepatol. 2013; 25: 784–9.

17 Stirling AD, Moran NR, Kelly ME, Ridgway PF, Conlon KC. The predictive value of C-reactive protein (CRP) in acute pancreatitis—is interval change in CRP an additional indicator of severity? HPB (Oxford). 2017; 19: 874–80.

18 Niemann A, Maksimow M, Mentula P et al. Circulating cytokines in predicting development of severe acute pancreatitis. Crit. Care. 2014; 18: R104.

19 Baudin G, Chassign M, Gelsi E et al. CT-guided percutaneous catheter drainage of acute infectious necrotizing pancreatitis: assessment of effectiveness and safety. Am. J. Roentgenol. 2012; 199: 192–9.

20 Kotan R, Sapy P, Pipka S et al. Serum C-reactive protein and white blood cell level as markers of successful percutaneous drainage of acute sterile peripancreatic fluid collection. Chirurgia. 2015; 110: 56–9.

21 Ai X, Qian X, Pan W et al. Ultrasound-guided percutaneous drainage may decrease the mortality of severe acute pancreatitis. J. Gastroenterol. 2010; 45: 77–85.
22 Liu WH, Ren LN, Chen T et al. Abdominal paracentesis drainage ahead of percutaneous catheter drainage benefits patients attacked by acute pancreatitis with fluid collections: a retrospective clinical cohort study. Crit. Care Med. 2015; 43: 109–19.
23 Navalho M, Pires F, Duarte A, Gonzalves A, Alexandrino P, Tavora I. Percutaneous drainage of infected pancreatic fluid collections in critically ill patients: correlation with C-reactive protein values. Clin. Imaging. 2006; 30: 114–9.
24 UK Working Party on Acute Pancreatitis. UK guidelines for the management of acute pancreatitis. Gut. 2005; 54: iii1–9.
25 Dellinger RP, Levy MM, Rhodes A et al. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock; 2012. Crit. Care Med. 2013; 41: 580–637.
26 Malbrain M, Jones F. Intra-abdominal pressure measurement techniques. In: Ivatury R, Cheatham M, Malbrain M, Sugrue M, eds., Abdominal Compartment Syndrome. Georgetown: Landes Bioscience, 2006; 19–68.
27 Bennett S, Lorenz JM. The role of imaging guided percutaneous procedures in the multidisciplinary approach to treatment of pancreatic fluid collections. Semin. Intervent. Radiol. 2012; 29: 314–8.
28 Sternby H, Hartman H, Johansen D, Thorlacius H, Regnér S. IL-6 and CRP are superior in early differentiation between mild and non-mild acute pancreatitis. Panreatology. 2017; 17: 550–4.
29 Stimac D, Fisic E, Milic S, Bilic-Zulle L, Peric R. Prognostic values of IL-6, IL-8, and IL-10 in acute pancreatitis. J. Clin. Gastroenterol. 2006; 40: 209–12.
30 Sathyanarayan G, Garg PK, Prasad H, Tandon RK. Elevated level of interleukin-6 predicts organ failure and severe disease in patients with acute pancreatitis. J. Gastroenterol. Hepatol. 2007; 22: 550–4.
31 Simovic MO, Bonham MJ, Abu-Zidan FM, Windsor JA. Anti-inflammatory cytokine response and clinical outcome in acute pancreatitis. Crit. Care Med. 1999; 27: 2662–5.
32 Brivet FG, Emilie D, Galanaud P. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis. Crit. Care Med. 1999; 27: 749–55.
33 Shen Y, Cui N, Miao B, Zhao E. Immune dysregulation in patients with severe acute pancreatitis. Inflammation. 2011; 34: 36–42.
34 Bakker OJ, van Santvoort HC, van Brunschot S et al. Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized trial. JAMA. 2012; 307: 1053–61.
35 Wang T, Liu LY, Luo H et al. Intra-abdominal pressure reduction after percutaneous catheter drainage is a protective factor for severe pancreatitis patients with sterile fluid collections. Pancreas. 2016; 45: 127–33.